

TABLE S1 Predictive impact of patient characteristics in patients treated with resection of tumour or/and adjuvant chemotherapy.

Author, year	No. pts.	Treatment	Stage	Patient characteristic	Patient characteristic status	Disease free survival			Overall survival		
						Months/ HR	p-value		Months/ HR/ 5- year survival (%)	p-value	
							Univariate	Multivariate		Univariate	Multivariate
Butts et al 2010	219	ACT (CDDP- based) or OP*	IB	Tumour size	Size ≥4 cm ACT vs. OP	NA	NA	NA	HR: 0.66	0.13	NA
					Size<4cm ACT vs. OP	NA	NA	NA	(0.39– 1.14) HR: 1.73 (0.98– 3.04)	0.056 (interaction p= 0.02)	NA
Strauss et al 2008	196	ACT (CBDCA+Pacl) or OP*	IB	Tumour size	Size ≥4 cm ACT vs. OP	HR: 0.69	0.035	NA	HR: 0.69	0.042	NA
					Size<4cm ACT	(0.49– 0.97)	0.49	NA	(0.48– 0.99)	0.32	NA

Author, year	No. pts.	Treatment	Stage	Patient characteristic	Patient characteristic status	Disease free survival			Overall survival		
						Months/ HR	p-value		Months/ HR/ 5- year survival (%)	p-value	
					vs. OP	HR: 1.01 (0.69– 1.48			HR:1.12 (0.75– 1.67)		
Nakagawa et al 2006	172	ACT (UFT) or OP*	I	Stage	T1 ACT vs. OP	NA	NA	NA	87.7% ¹ vs.	0.014	NA
					T2 ACT vs. OP	NA	NA	NA	56.4% ¹ vs. 58.5% 59.4% ¹	0.763	NA
Nakagawa	172	ACT (UFT) or	I	Gender	Male ACT vs.	NA	NA	NA	71.6% ¹	0.013	NA

Author, year	No. pts.	Treatment	Stage	Patient characteristic	Patient characteristic status	Disease free survival			Overall survival			
						Months/ HR	p-value		Months/ HR/ 5- year survival (%)	p-value		
							Univariate	Multivariate		Univariate	Multivariate	
et al 2006		OP*			OP	NA	NA	NA	vs.	43.6% ¹	0.850	NA
					Female ACT vs. OP					78% ¹ vs. 74.7% ¹		
Bennouna et al 2011	840	ACT (CDDP+NVB) or OP*	IB– IIIA	Histology	Adenocarcinoma ACT vs. OP	NA	NA	NA		52.1% vs.	NA	NA
					Other ACT vs. OP	NA	NA	NA		38.2% 50.8% vs. 45% HR: 0.71	NA	NA

Author, year	No. pts.	Treatment	Stage	Patient characteristic	Patient characteristic status	Disease free survival			Overall survival		
						Months/ HR	p-value		Months/ HR/ 5- year survival (%)	p-value	
							Univariate	Multivariate		Univariate	Multivariate
									(0.52– 0.97)		

Abbreviations: No. pts: number of patients, HR: Hazard ratio, ACT: adjuvant chemotherapy, CDDP= cisplatin, OP= complete surgery only, NA: not available, CBDCA: carboplatin, Pacl: Paclitaxel, UFT: uracil-tegafur, NVB: Vinorelbine NA: not available, HR: Hazard ratio. *Randomized trial. ACT-group and OP-group (control-group). 18-year survival

TABLE S2 Prognostic impact of patient characteristics in patients treated with resection of tumour or/and adjuvant chemotherapy

Author, year	No. pts.	Treatment	Stage	Patient characteristics	Patient characteristics status	Disease free survival			Overall survival		
						Months/ HR	p-value		Months/ HR	p-value	
							Univariate	Multivariate		Univariate	Multivariate
Scagliotti et al 2003	548	ACT (CDDP- based) or OP*	I–III	Gender	Male	NA	NA	NA	HR: 1.33 (1.02– 1.72)	NA	0.034
					Female	NA		NA		NA	

Author, year	No. pts.	Treatment	Stage	Patient characteristics	Patient characteristics status	Disease free survival			Overall survival			
						Months/ HR	p-value Univariate Multivariate		Months/ HR	p-value Univariate Multivariate		
									1			
Kato et al 2004	999	ACT (UTF) or OP*	I	Gender	Female	NA	NA	NA	HR: 0.66 (0.48– 0.91)	NA	NA	0.01
					Male	NA	NA	NA	1	NA	NA	NA
Takenaka et al 2010	122	ACT (FU) or OP**	I–III	Gender	Male	HR: 5.4 (1.61– 18.2)	NA	0.03	NA	NA	NA	NA
					Female	1	NA	NA	NA	NA	NA	NA
Scagliotti et al 2003	548	ACT (CDDP- based) or OP*	I–III	Stage	III	2.94 (2.39– 3.53)	0.001	NA	HR: 3.19 (2.59– 3.93)	NA	NA	0.001
					I	1		NA	1			

Author, year	No. pts.	Treatment	Stage	Patient characteristics	Patient characteristics status	Disease free survival			Overall survival		
						Months/HR	Univariate	Multivariate	Months/HR	Univariate	Multivariate
Douillard et al 2006	407	ACT (CDDP+NVB) or OP*	I– IIIA	Stage	IIIA	NA	NA	NA	HR: 0.64 (0.52–	NA	0.001
					I–II	NA	NA	NA	0.78)	NA	
Yan et al 2010	151	ACT (Pacl-, Gem-, NVB- or Doc- based) ***	I–III	Stage	III	HR: 1.688 (1.291–	NA	0.001	NA	NA	NA
					I–II	2.208)	NA	NA	NA	NA	
Takenaka et al 2010	122	ACT (FU) or OP**	I–III	Stage	III	HR: 9.4 (4.2–	NA	0.001	HR: 13.7 (4.3–	NA	0.001
					I–II	21.4)	NA	44.1)	NA		

Author, year	No. pts.	Treatment	Stage	Patient characteristics	Patient characteristics status	Disease free survival			Overall survival		
						Months/ HR	p-value		Months/ HR	p-value	
						Univariate	Multivariate		Univariate	Multivariate	
Kato et al 2004	999	ACT (UTF) or OP*	I	T-stage	T2	NA	NA	NA	HR: 1.95	NA	0.001
					T1	NA	NA	NA	(1.41– 2.69)	NA	
Yan et al 2010	151	ACT (Pacl-, Gem-, NVB- or Doc- based)***	I–III	Histology	Adenocarcinoma	HR: 2.14	NA	0.001	NA	NA	NA
					Other	(1.37– 3.37)	NA	NA	NA	NA	
Shi et al 2011	144	ACT (Pacl-, Gem-, NVB- or Doc- based) **	I–III	Histology	Adenocarcinoma	15.7	0.006	0.0001	NA	NA	NA
					Other	48.2	HR: 2.9	NA	NA	NA	
Takenaka et al 2010	122	ACT (FU) or OP**	I–III	Histology	Adenocarcinoma	HR: 0.42	0.04	0.25	NA	NA	NA

Author, year	No. pts.	Treatment	Stage	Patient characteristics	Patient characteristics status	Disease free survival			Overall survival		
						Months/ HR	p-value		Months/ HR	p-value	
					Other	(0.18– 0.94)			NA	NA	NA
Nakagawa et al 2006	172	ACT (UFT) or OP*	I	Age	≥60 years	NA	NA	NA	HR: 2.24	NA	0.0053
					<60 years	NA	NA	NA	(1.26– 4.20)	NA	
Kato et al 2004	999	ACT (UTF) or OP*	I	Age	≥65 years	NA	NA	NA	HR:2.02	NA	0.001
					<65 years	NA	NA	NA	(1.46– 2.80)	NA	
Douillard et al 2006	407	ACT (CDDP+NVB) or OP*	I– IIIA	Age	<55 years	NA	NA	NA	HR: 0.76	NA	0.005
					≥55 years	NA	NA	NA	(0.62– 0.93)	NA	
									1		

Abbreviations: No. pts: number of patients, HR: Hazard ratio, ACT: adjuvant chemotherapy, CDDP= cisplatin, OP= complete surgery only, NA: not available, UFT: uracil-tegafur, FU: Fluorouracil, NVB: Vinorelbine, Pacl: Paclitaxel, Gem: Gemcitabine, Doc: Docetaxel. *Randomized trial. ACT-group and OP-group (control-group). ** Not randomized patients. ACT-group and OP-group (control-group). *** Not randomized patients. Only ACT-patients.

References

Butts CA., Ding K., Seymour L., *et al.* Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. *J Clin Oncol* 2010; 28: 29–34.

Strauss GM., Herndon JE 2nd., Maddaus MA., *et al.* Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. *J Clin Oncol* 2008; 26: 5043–5051.

Nakagawa K., Tada H., Akashi A., *et al.* Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIa non-small cell lung cancer. *Br J Cancer* 2006; 95: 817–821.

Bennouna J., Senellart H., Hiret S., *et al.* Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) *versus* observation in the ANITA trial. *Lung Cancer* 2011; 74: 30–34.

Scagliotti GV., Fossati R., Torri V., *et al.* Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. *J Natl Cancer Inst* 2003; 95: 1453–1461.

Kato H., Ichinose Y., Ohta M., *et al.* A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. *N Engl J Med* 2004; 350: 1713–1721.

Takenaka T., Yano T., Kiyohara C., *et al.* Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. *Lung Cancer* 2010; 67: 101–107.

Douillard JY., Rosell R., De Lene M., *et al.* Adjuvant vinorelbine plus cisplatin *versus* observation in patients with completely resected stage IB-III A non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006; 7: 719–727.

Yan S., Shun-Chang J., Li C., *et al.* Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. *BMC Cancer* 2010; 10: 621.

Shi Y., Chen L., Li J., *et al.*: Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.: *Tumour Biol* 2011; 32: 381–390.